002620 — Jeil Pharma Holdings Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapNeutral

Annual cashflow statement for Jeil Pharma Holdings, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-95,854	14,941	-12,870	-83,145	-13,241
Depreciation
Amortisation
Non-Cash Items	106,218	8,940	10,760	77,504	28,548
Unusual Items
Purchased R&D
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	7,069	-56,203	6,530	-26,066	-32,279
Change in Accounts Receivable
Change in Inventories
Change in Other Assets
Change in Accounts Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	25,216	-23,671	13,403	-20,802	-4,416
Capital Expenditures	-1,660	-10,267	-23,736	-21,410	-9,837
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-39,188	8,661	31,061	3,846	-3,588
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Sale of Intangible Assets
Other Investing Cash Flow
Cash from Investing Activities	-40,847	-1,606	7,325	-17,564	-13,425
Financing Cash Flow Items	-8,301	-315	-810	—	—
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-3,888	24,894	-12,238	44,914	20,616
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	-19,861	-1,054	8,397	6,179	2,279